Trillium Therapeutics Provides Update On Phase I Dose Escalation Study Of CD47 Blocker TTI-622 At ASCO20; Dosing Has Progressed Through First Five Cohorts Up To 4 Mg/Kg Dose Level, Strong Safety Profile, With No Dose-limiting Toxicities Observed

Author: Benzinga Newsdesk | May 29, 2020 08:30am

 

• Dosing has progressed through first five cohorts up to 4 mg/kg dose level
• Strong safety profile, with no dose-limiting toxicities observed
• Monotherapy activity (1 CR and 1 PR) observed in DLBCL patients
• Further dose escalation is underway, currently dosing at 8 mg/kg

CAMBRIDGE, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today data from an ongoing phase 1 dose escalation study of TTI-622 in patients with advanced relapsed or refractory lymphoma. The data are being presented today at a poster session at the ASCO20 Virtual Scientific Program. TTI-622 is an innate immune checkpoint inhibitor targeting CD47, a “do not eat me” signal that cancer cells use to evade destruction by the immune system.

“The data emerging from this dose escalation study suggest that TTI-622 is a promising and highly differentiated CD47 blocker,” said Jan Skvarka, President and Chief Executive Officer of Trillium. “We are seeing strong tolerability, consistent with the red blood cell-sparing property associated with this molecule. Both drug exposure and target engagement have shown dose response relationships. Notably, in addition to the previously reported monotherapy complete response, we have observed a partial response in a second DLBCL patient.”

The poster (#94, abstract #3030), entitled “Ongoing, First-in-human, Phase 1 Dose Escalation Study of the Investigational CD47-blocker TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma”, will be presented by lead author Krish Patel, MD, Director of the Lymphoma Program at the Swedish Cancer Institute in Seattle. It will be available on the meeting website beginning at 8 a.m. ET on Friday, May 29 in the Developmental Therapeutics – Immunotherapy session. A copy of the poster will also be available on the Events and Presentations page of Trillium’s website.

Highlights from the Phase I Study Update

• The presentation reports on data from 19 relapsed/refractory lymphoma patients who were enrolled in the first 5 cohorts, and were treated with TTI-622 monotherapy at a dose of up to 4 mg/kg.
• Weekly intravenous infusions of TTI-622 were shown to be well tolerated, with no dose-limiting toxicities or drug-related grade ≥3 anemia or thrombocytopenia.
• Preliminary data indicate dose-dependent increases in both drug exposure and target engagement, with receptor occupancy levels above 60% at doses of 2 mg/kg measured immediately after and 24 hours after infusion administration.
• Objective responses were observed in two heavily pretreated diffuse large B-cell lymphoma (DLBCL) patients. One patient achieved a partial response (PR) at week 8 and a complete response (CR) at week 36; a second patient achieved a PR at week 8. Both patients have been continuing on study for 340 and 90 days, respectively, as of April 24, 2020.
• Further dose escalation is in progress. The study is currently dosing at 8 mg/kg

Posted In: TRIL TSX:TRIL